Harry Burrell

Lucigen Corp. engages in the development, manufacture, and sale of biomedical research products and services. The firm offers products for array-based analysis; cloning kits and vectors; competent cells; enzymes; in vitro transcription; next gen sequencing (NGS); nucleic acid extraction and purification; PCR and amplification; protein expression; and transposon mutagenesis. It also provides NGS and custom competent cell services. The company was founded by David Mead and Thomas W. Schoenfeld in 1998 and is headquartered in Middleton, WI.

Lucigen Corp. engages in the development, manufacture, and sale of biomedical research products and services. The firm offers products for array-based analysis; cloning kits and vectors; competent cells; enzymes; in vitro transcription; next gen sequencing (NGS); nucleic acid extraction and purification; PCR and amplification; protein expression; and transposon mutagenesis. It also provides NGS and custom competent cell services. The company was founded by David Mead and Thomas W. Schoenfeld in 1998 and is headquartered in Middleton, WI.

Lucigen Corp. engages in the development, manufacture, and sale of biomedical research products and services. The firm offers products for array-based analysis; cloning kits and vectors; competent cells; enzymes; in vitro transcription; next gen sequencing (NGS); nucleic acid extraction and purification; PCR and amplification; protein expression; and transposon mutagenesis. It also provides NGS and custom competent cell services. The company was founded by David Mead and Thomas W. Schoenfeld in 1998 and is headquartered in Middleton, WI.